Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program
Epilepsia · 2024-10 · 65 (10) · 2909-2922
DOI: 10.1111/epi.18091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, online erschienen am 14.08.2024. Verfasst von Roberta Roberti und 25 weiteren Autor:innen. Beteiligte Einrichtung: Science of Health Department, Magna Graecia University, Catanzaro, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Partial, Carbamates, Chlorophenols. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study was undertaken to assess the effectiveness/tolerability of adjunctive cenobamate, variations in the load of concomitant antiseizure medications (ASMs) and predictors of clinical response in people with focal epilepsy.
Methods
This was a retrospective study at 21 centers participating in the Italian Expanded Access Program. Effectiveness outcomes included retention and responder rates (≥50% and 100% reduction in baseline seizure frequency). Tolerability/safety outcomes included the rate of treatment discontinuation due to adverse events (AEs) and their incidence. Total drug load was quantified as the number of concomitant ASMs and total defined daily dose (DDD). Concomitant ASMs were also classified according to their mechanism of action and pharmacokinetic interactions to perform explorative subgroup analyses.
Results
A total of 236 subjects with a median age of 38 (Q 1 –Q 3 = 27–49) years were included. At 12 months, cenobamate retention rate was 78.8% and responders were 57.5%. The seizure freedom rates during the preceding 3 months were 9.8%, 12.2%, 16.3%, and 14.0% at 3, 6, 9, and 12 months. A higher percentage of responders was observed among subjects treated with clobazam, although the difference was not statistically significant. A total of 223 AEs were recorded in 133 of 236 participants, leading to cenobamate discontinuation in 8.5% cases. At 12 months, a reduction of one or two concomitant ASMs occurred in 42.6% and 4.3% of the subjects. The median total DDD of all concomitant ASMs decreased from 3.34 (Q 1 –Q 3 = 2.50–4.47) at baseline to 2.50 (Q 1 –Q 3 = 1.67–3.50) at 12 months ( p < .001, median percentage reduction = 22.2%). The highest rates of cotreatment withdrawal and reductions in the DDD were observed for sodium channel blockers and γ‐aminobutyric acidergic modulators (above all for those linked to pharmacokinetic interactions), and perampanel. Significance Adjunctive cenobamate was associated with a reduction in seizure frequency and in the burden of concomitant ASMs in adults with difficult‐to‐treat focal epilepsy. The type of ASM associated did not influence effectiveness except for a favorable trend with clobazam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science of Health Department, Magna Graecia University, Catanzaro, Italy.
- Department of Medicine and Surgery, Research Unit of Neurology, Università Campus Bio-Medico, Rome, Italy.
- Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche di Bologna, full member of the European Reference Network EpiCARE, Bologna, Italy.
- Complex Structure of Neurology Hospital Santissima, Annunziata, Taranto, Italy.
ORCID-Profile: Francesca Bisulli, Laura Canafoglia, Carlo Di Bonaventura, Maurizio Elia, Claudio Liguori, Stefano Meletti, Francesca Felicia Operto, Elena Tartara, Emilio Russo, Simona Lattanzi
Zitieren
APA
Roberti, R., Assenza, G., Bisulli, F., Boero, G., Canafoglia, L., Chiesa, V., Di Bonaventura, C., Di Gennaro, G., Elia, M., Ferlazzo, E., Giordano, A., La Neve, A., Liguori, C., Meletti, S., Operto, F. F., Pietrafusa, N., Puligheddu, M., Pulitano, P., Rosati, E., …, & Lattanzi, S. (2024). Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program. Epilepsia, 65(10), 2909-2922. https://doi.org/10.1111/epi.18091
Vancouver
Roberti R, Assenza G, Bisulli F, Boero G, Canafoglia L, Chiesa V, et al. Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program. Epilepsia. 2024;65(10):2909-2922. doi:10.1111/epi.18091
BibTeX
@article{Roberti2024,
author = {Roberti, Roberta and Assenza, Giovanni and Bisulli, Francesca and Boero, Giovanni and Canafoglia, Laura and Chiesa, Valentina and Di Bonaventura, Carlo and Di Gennaro, Giancarlo and Elia, Maurizio and Ferlazzo, Edoardo and Giordano, Alfonso and La Neve, Angela and Liguori, Claudio and Meletti, Stefano and Operto, Francesca Felicia and Pietrafusa, Nicola and Puligheddu, Monica and Pulitano, Patrizia and Rosati, Eleonora and Sammarra, Ilaria and Tartara, Elena and Vatti, Giampaolo and Villani, Flavio and CNB EAP Italy Study Group, CNB EAP Italy Study Group and Russo, Emilio and Lattanzi, Simona},
title = {Adjunctive cenobamate in people with focal onset seizures: Insights from the Italian Expanded Access Program},
journal = {Epilepsia},
year = {2024},
volume = {65},
number = {10},
pages = {2909--2922},
doi = {10.1111/epi.18091}
}
EUVIMED